SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by renewed tariff threats against European allies, tied to geopolitical tensions over Greenland, sparking widespread market apprehension. The community is sharply divided between those anticipating a major pullback and those expecting a rapid "buy the dip" recovery, citing the market's historical resilience to such headlines. This situation unfolds as participants also eye a potential Supreme Court ruling on tariffs, which could further influence market direction.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is drawing considerable attention following its recent acquisition of VLX-1005, expanding its pipeline beyond a single asset, alongside ongoing progress for its flagship tecarfarin toward Phase 3 trials and manufacturing readiness. The community is actively debating its ultra-low float and the potential for tecarfarin to revolutionize anticoagulation therapy, with some analysts issuing high price targets. This discussion is set against concerns over past offerings and potential dilution, highlighting a polarized but active market interest in the microcap biotech.

KiboShib (KIBSHI) is the first AI-generated meme coin. On December 8th 2022, AI was tasked with creating a meme coin. It all started as a joke, but the idea which was proposed by the AI is so powerful that nobody could resist! The AI even suggested a logo design which later has been fed to the AI image generator. The age of AI is upon us, and KiboShib stands for exploring the capabilities of AI with a hopeful outlook.

KiboShib

KIBSHI CRYPTO is trending as the community rallies around its unique narrative as the first AI-generated meme coin, created by ChatGPT in 2022. This narrative, combined with growing AI hype, fuels discussions about its potential for substantial gains, with many comparing it to the early explosive runs of $DOGE and $SHIB. Investors are actively discussing its low market capitalization and positioning for what they anticipate could be a significant opportunity in the upcoming altcoin cycle.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid high anticipation for Supreme Court rulings on tariffs and escalating market debate over political influence on Federal Reserve policy. Community discussions are sharply divided, with some foreseeing disinflation and rate cuts supporting long-term bonds, while others remain concerned about geopolitical tensions and national debt sustaining higher yields. These intertwined factors are fueling significant uncertainty and varied trading strategies for the Treasury bond ETF.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid heightened geopolitical tensions sparked by recent tariff threats between the U.S. and European nations concerning Greenland, triggering a broad risk-off sentiment and significant liquidations in the crypto market. The community is actively debating whether this presents a buying opportunity or signals further declines, with many questioning Bitcoin's role as a safe haven asset amidst the escalating global uncertainty.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending as the community eagerly discusses its strong pivot into the AI narrative, with an anticipated rebrand to "Rose AI." Its foundational role in privacy-preserving AI, confidential computing, and Web3 developments is generating significant enthusiasm, positioning it as an undervalued asset with substantial growth potential.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as the broader biotech sector experiences a significant rally, driven by accelerating advancements in AI-driven drug discovery and widespread anticipation of future Fed rate cuts. Community discussion highlights strong bullish sentiment, with many speculating about continued upward momentum and a rotation of capital into the sector.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as the S&P Biotech Select Industry Index (XBI) shows unusual resilience and continued bullish momentum, leading to significant frustration among investors anticipating a sector pullback. Despite widespread calls for a reversal based on technical divergences and broader economic concerns, XBI's strength, potentially fueled by M&A and market rotation, has left many "bag holding" this inverse ETF while keenly debating future entry opportunities.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing a surge in attention following significant global approvals for its Anktiva cancer therapy, notably for lung and bladder cancer, challenging established treatment paradigms. This development, combined with high short interest and the company's leadership actively promoting the science, has fueled community discussions around a potential short squeeze and a transformative shift in the biotech sector. Investors are keenly focused on the accelerated revenue prospects and broader market adoption of these innovative treatments.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is trending with recent strong upward price action, fueled by strategic route expansions and the completion of its more efficient all-Airbus fleet transition. The community is actively discussing potential for a short squeeze and anticipating a significant move higher, particularly as lower fuel costs are expected to boost upcoming earnings.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of <a href="https://stocktwits.com/symbol/ATHE">Alterity Therapeutics</a> soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average.The clinical-stage biotech announced positive Phase 2 results for ATH434, its oral treatment for early-stage multiple system atrophy (MSA)— a rare neurodegenerative disease.Key findings from the 52-week trial:<ul style="list-style-type:square;"><li>50 mg dose: 48% reduction in clinical progression vs. placebo</li><li>75 mg dose: 29% reduction in clinical progression vs. placebo</li></ul>The 50 mg dose reduced iron accumulation in multiple system atrophy-affected brain regions, while the 75 mg dose specifically reduced iron buildup in the globus pallidus.CEO David Stamler said, “Currently, there are no approved treatments that slow the progression of MSA, and these results show ATH434’s targeted iron engagement may truly have a disease-modifying effect.”<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATHE_sentiment_and_message_volume_Jan_30_premarket_df297a4b9a.png" alt="ATHE sentiment and message volume Jan 30 premarket.png" width="1318" height="324"><figcaption>ATHE sentiment and message volume Jan 30 premarket as of 9 am ET | source: Stocktwits</figcaption></figure>Stocktwits message volume for Alterity skyrocketed, hitting ‘extremely high’ levels ahead of Thursday’s&nbsp;opening bell, with sentiment hitting the highest reading in over a year.Some users predicted ATHE could more than triple, stabilizing around $10, while others reiterated their bullish stance on the drug’s market potential.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/602113870</stembedurl><stembedurl>https://stocktwits.com/DaBullRunner/message/602113078</stembedurl>ATHE was among the top three trending tickers on Stocktwits early Thursday.&nbsp;Message volume around the stock on the platform has surged 700% over the past year, during which it has gained 46%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Equity

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

ATHE
Alterity Therapeutics Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest ATHE News

ATHEAlterity Therapeutics Ltd - ADR